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ABSTRACT
Neuroblastoma is the most common solid tumor during early childhood. One 
of the key features of neuroblastoma is extensive tumor-driven angiogenesis due 
to hypoxia. However, the mechanism through which neuroblastoma cells drive 
angiogenesis is poorly understood. Here we show that the long noncoding RNA 
MALAT1 was upregulated in human neuroblastoma cell lines under hypoxic conditions. 
Conditioned media from neuroblastoma cells transfected with small interfering RNAs 
(siRNA) targeting MALAT1, compared with conditioned media from neuroblastoma 
cells transfected with control siRNAs, induced significantly less endothelial cell 
migration, invasion and vasculature formation. Microarray-based differential 
gene expression analysis showed that one of the genes most significantly down-
regulated following MALAT1 suppression in human neuroblastoma cells under hypoxic 
conditions was fibroblast growth factor 2 (FGF2). RT-PCR and immunoblot analyses 
confirmed that MALAT1 suppression reduced FGF2 expression, and Enzyme-Linked 
Immunosorbent Assays revealed that transfection with MALAT1 siRNAs reduced FGF2 
protein secretion from neuroblastoma cells. Importantly, addition of recombinant 
FGF2 protein to the cell culture media reversed the effects of MALAT1 siRNA on 
vasculature formation. Taken together, our data suggest that up-regulation of MALAT1 
expression in human neuroblastoma cells under hypoxic conditions increases FGF2 
expression and promotes vasculature formation, and therefore plays an important 
role in tumor-driven angiogenesis.
INTRODUCTION
Neuroblastoma, originating from precursor 
neuroblast cells in the sympathetic nervous system, is 
the most common extracranial malignancy in children, 
and accounts for 15% of all childhood cancer deaths [1]. 
One of the key features of human neuroblastoma tissues is 
extensive tumor-driven angiogenesis [2].
Angiogenesis is a pre-requisite for tumor 
progression and metastasis [3]. When placed in a state of 
prolonged or severe reduction of tissue oxygen tension, or 
hypoxia, cancer cells undergo adaptive changes that allow 
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them to up-regulate the expression of pro-angiogenic 
genes, leading to tumor-driven angiogenesis, tumor cell 
survival, proliferation and metastasis [4]. The genes 
most important for the tumor-driven angiogenic switch 
include Hypoxia-Inducible Factor 1α (HIF1α), Vascular 
Endothelial Growth Factor and Fibroblast Growth Factor 
2 (FGF2) [5].
Long noncoding RNAs (lncRNAs) are transcripts 
more than 200 nucleotides in length without a functional 
open reading frame. According to their genetic location in 
relation to neighbouring protein-coding genes, lncRNAs 
can be divided into sense, antisense, bidirectional, intronic 
and intergenic subtypes [6, 7]. In the last several years, 
lncRNAs have emerged as essential mediators of gene 
transcription, mRNA stabilization/degradation, cell 
proliferation, survival, tumour initiation and metastasis 
[6, 7]. For example, the lncRNA lncUSMycN binds 
to the RNA-binding protein NonO and up-regulates 
N-Myc mRNA and protein expression [8]. The lncRNA 
lincRNA-p21 is directly up-regulated by the tumor 
suppressor p53 and plays an important role in p53-
regulated apoptosis [9]. In addition, the lncRNA HOTAIR 
regulates the expression of genes critical for tumor cell 
invasion, and plays a critical role in breast cancer cell 
invasion and metastasis [10].
The long intergenic noncoding RNA MALAT1, 
also known as NEAT2, is over-expressed in metastatic, 
compared with primary, cancer tissues, and high levels of 
MALAT1 expression in cancer tissues correlate with poor 
patient prognosis [11–13]. Recent studies have shown 
that MALAT1 suppression impairs cancer cell migration, 
invasion and metastasis, suggesting an important role of 
MALAT1 in cancer metastasis [12, 14, 15].
We have previously shown that MALAT1 gene 
expression is up-regulated by the histone demethylase 
JMJD1A in neuroblastoma cells, and that MALAT1 
induces neuroblastoma cell migration and invasion 
[16]. In this study, we examined the role of MALAT1 in 
tumor-driven angiogenesis. Our results showed that up-
regulation of MALAT1 in neuroblastoma cells as a result 
of hypoxia, induced endothelial cell migration, invasion 
and vasculature formation. The mechanism of action 
mediating these effects involved up-regulation of the pro-
angiogenic factor, FGF2.
RESULTS
Hypoxia increases MALAT1 gene expression 
but MALAT1 does not affect cell proliferation 
in neuroblastoma cells
Since MALAT1 is well-known to be over-expressed 
in metastatic, compared with primary, human tumor tissues 
[11, 12, 17], and hypoxia is known to induce tumour cell 
metastasis, we examined whether hypoxia up-regulated 
MALAT1 gene expression in human neuroblastoma cell 
lines. As shown in Figure 1A, MALAT1 gene expression 
was increased in human neuroblastoma BE(2)-C and Kelly 
cells cultured under hypoxic conditions (1% O2) for 48 
hours, by comparison with cells cultured under normoxic 
conditions. To determine whether MALAT1 plays a role in 
neuroblastoma cell proliferation, we transfected BE(2)-C 
and Kelly cells with control siRNA or independent 
MALAT1 siRNAs (MALAT1 siRNA-1 or MALAT1 
siRNA-2) under hypoxic conditions, followed by RT-PCR 
analysis of MALAT1 gene expression and Alamar blue 
assays of the numbers of cells. RT-PCR analysis confirmed 
that MALAT1 siRNAs reduced MALAT1 gene expression 
(Figure 1B), but Alamar blue assays showed that knocking-
down MALAT1 expression did not have an effect on the 
numbers of neuroblastoma cells (Figure 1C). The data 
suggest that MALAT1 gene expression is up-regulated by 
hypoxia but MALAT1 does not modulate neuroblastoma 
cell proliferation under hypoxic conditions.
MALAT1 expression in neuroblastoma cells 
induces endothelial cell migration, invasion 
and vasculature formation
We have previously shown that up-regulation of 
MALAT1 gene expression induces neuroblastoma cell 
migration and invasion [16]. We next examined whether 
knocking-down endogenous MALAT1 expression in 
neuroblastoma cells under hypoxic conditions modulated 
endothelial cell migration, invasion and vasculature 
formation. BE(2)-C and Kelly neuroblastoma cells were 
transfected with control siRNA, MALAT1 siRNA-1 
or MALAT1 siRNA-2 under hypoxic conditions for 
72 hours. Conditioned cell culture media were collected 
and added to HUVEC cells for HUVEC cell trans-well 
migration, trans-matrigel invasion and vasculature 
formation assays. As shown in Figure 2A, HUVEC cell 
migration was significantly reduced when stimulated 
with conditioned media from BE(2)-C and Kelly cells 
transfected with MALAT1 siRNAs, compared with 
control siRNA. Likewise, HUVEC cell invasion through 
matrigel and vasculature formation were both significantly 
reduced when stimulated with conditioned media from 
BE(2)-C and Kelly cells transfected with MALAT1 
siRNAs, compared with control siRNA (Figures 2B, 
2C). Taken together, the data suggest that up-regulation 
of MALAT1 in neuroblastoma cells under hypoxic 
conditions stimulates endothelial cell migration, invasion 
and vasculature formation.
MALAT1 expression in endothelial cells 
induces vasculature formation
We next examined whether MALAT1 expression 
in endothelial cells stimulates vasculature formation. 
As shown in Figure 3A and Figure 3B, MALAT1 gene 
expression was significantly lower in HUVEC cells than 
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in BE(2)-C and Kelly neuroblastoma cells (Figure 3A), 
and MALAT1 gene expression was not altered in HUVEC 
cells under hypoxic conditions, compared with those under 
normoxic conditions (Figure 3B). While transfection with 
MALAT1 siRNAs significantly reduced MALAT1 gene 
expression (Figure 3C), Alamar blue assays showed that 
knocking-down MALAT1 had no effect on HUVEC cell 
proliferation (Figure 3D). For vasculature formation 
assays, HUVEC cells were transfected with control 
siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 for 72 
hours under either normoxia or hypoxia. Cells were then 
detached, and equal numbers of transfected cells were 
cultured on matrigel for 6 hours. As shown in Figure 3E, 
hypoxic conditions, compared with normoxic conditions, 
reduced vasculature formation capacity of HUVEC cells. 
Importantly, under both normoxic and hypoxic conditions, 
knocking-down MALAT1 significantly reduced 
vasculature formation (Figure 3E). The data suggest 
that MALAT1 expression in endothelial cells induces 
vasculature formation.
Figure 1: Hypoxia increases MALAT1 gene expression but MALAT1 does not affect cell proliferation in neuroblastoma 
cells. A. BE(2)-C and Kelly neuroblastoma cells were cultured under normoxic or hypoxic conditions for 48 hours, followed by RT-PCR 
analysis of MALAT1 gene expression. B. BE(2)-C and Kelly cells were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 
siRNA-2 for 48 hours under hypoxic conditions, followed by RT-PCR analysis of MALAT1 gene expression. C. BE(2)-C and Kelly cells 
were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 for 72 hours under hypoxic conditions, followed by 
Alamar blue assays to quantitate viable cell numbers. Relative numbers of cells were expressed as a percentage change compared with 
samples transfected with control siRNA. Error bars represented standard error. ** and *** indicated P < 0.01 and 0.001 respectively.
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Figure 2: MALAT1 expression in neuroblastoma cells induces endothelial cell migration, invasion and vasculature 
formation. BE(2)-C and Kelly neuroblastoma cells were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 
for 72 hours under hypoxic conditions, and cell culture media were collected. A. For HUVEC cell migration assays, the conditioned cell 
culture media were added into fluorescently labeled HUVEC cells in the upper part of chemotaxis chambers. HUVEC cells were allowed to 
migrate through 8-μm pore polyethylene terephthalate membrane towards chemoattractants in the lower part of the chemotaxis chambers 
for 6 hours. The lower part of the chemotaxis chamber was read with a fluorescence plate reader at 492/517 nm, and the relative numbers 
of HUVEC cells were calculated. B. For HUVEC cell invasion assays, the neuroblastoma cell conditioned media were added into the 
lower part of cell invasion chambers. HUVEC cells were plated into the upper part of the invasion chambers and allowed to invade through 
membranes coated with matrigel towards the conditioned cell culture media overnight for 18 hours at 37°C. Cells invaded to the other side 
of the membrane were then fixed, stained, visualized under a microscope and quantified. C. For vasculature formation assays, HUVEC cells 
were cultured in matrigel-coated 24-well plates and the neuroblastoma cell conditioned media were added to the HUVEC cells for 8 hours 
at 37°C. Photographs of vascular structures were taken using a 5 × objective. Vasculature formation was evaluated by measuring the total 
surface area of capillary tubes formed in at least 10 randomly selected fields per well. Scale bars represented 100 μm. Error bars represented 
standard error. ** and *** indicated p < 0.01 and 0.001 respectively.
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Figure 3: MALAT1 expression in endothelial cells induces vasculature formation. A. RNA was extracted from BE(2)-C 
and Kelly neuroblastoma and HUVEC cells under hypoxic conditions, followed by RT-PCR analysis of MALAT1 gene expression. 
B. HUVEC cells were cultured under normoxic or hypoxic conditions for 48 hours, followed by RT-PCR analysis of MALAT1 gene 
expression. C. HUVEC cells were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 for 48 hours under hypoxic 
conditions, followed by RT-PCR analysis of MALAT1 gene expression. D. HUVEC cells were transfected with control siRNA, MALAT1 
siRNA-1 or MALAT1 siRNA-2 for 72 hours under hypoxic conditions, followed by Alamar blue assays. Relative numbers of cells were 
expressed as a percentage change compared with samples transfected with control siRNA. E. For vasculature formation assays, HUVEC 
cells were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 and cultured under normoxia or hypoxia conditions 
for 72 hours. Equal numbers of transfected HUVEC cells were then plated into matrigel coated 24-well plates for 8 hours. Photographs of 
vascular structures were taken using a 5 × objective. Vasculature formation was evaluated by measuring the total surface area of capillary 
tubes formed in at least 10 randomly selected fields per well. Scale bars represented 100 μm. Error bars represented standard error. * and 
*** indicated p < 0.05 and 0.001 respectively.
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MALAT1 up-regulates FGF2 gene expression in 
neuroblastoma cells and FGF2 protein secretion 
under hypoxic conditions
Since long noncoding RNAs exert biological effects 
by modulating gene expression [6, 18], we performed 
differential gene expression studies using Affymetrix 
microarray in BE(2)-C cells after transfection with control 
siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 for 30 
hours. The microarray data showed that one of the genes 
significantly down-regulated by MALAT1 was FGF2 
(Table 1), which is well known to induce angiogenesis 
[19]. Real-time RT-PCR studies confirmed that hypoxia, 
compared with normoxia, and immunoblot studies under 
hypoxia, increased FGF2 gene expression in BE(2)-C and 
Kelly neuroblastoma cells (Figure 4A), and that knocking-
down MALAT1 with siRNAs reduced FGF2 mRNA 
and protein expression in BE(2)-C and Kelly cells under 
hypoxic conditions (Figures 4B, 4C).
Pro-angiogenic factors are secreted into extracellular 
fluid, and thereafter stimulate endothelial cell function. 
We therefore examined whether MALAT1 regulated 
FGF2 protein secretion into cell culture media. Enzyme-
linked immunosorbent assay (ELISA) was performed with 
conditioned cell culture media from BE(2)-C and Kelly 
cells 72 hours after transfection with control siRNA, 
MALAT1 siRNA-1 or MALAT1 siRNA-2 under hypoxic 
conditions. Knocking-down MALAT1 expression with 
siRNAs consistently reduced the levels of FGF2 protein 
in cell culture media (Figure 4D). Taken together, the data 
suggest that MALAT1 up-regulates FGF2 gene expression 
in neuroblastoma cells and FGF2 protein secretion into 
extracellular fluid under hypoxic conditions.
MALAT1-mediated FGF2 protein secretion 
from neuroblastoma cells induces vasculature 
formation
We next examined whether increased secretion of 
FGF2 protein from neuroblastoma cells was responsible 
for MALAT1-mediated endothelial cell function. BE(2)-C 
and Kelly cells were transfected with control siRNA, 
MALAT1 siRNA-1 or MALAT1 siRNA-2 for 72 hours 
under hypoxic condition. Conditioned cell culture media 
were collected and divided into two sub-groups. For one 
sub-group, recombinant FGF2 protein was added into 
conditioned cell culture media from cells transfected 
with MALAT1 siRNAs and equal amount of bovine 
serum albumin (BSA) was added into conditioned cell 
culture media from cells transfected with control siRNA, 
according to the ELISA data (Figure 4D), so that the 
levels of FGF2 protein in MALAT1 siRNA-transfected 
samples were the same as in control siRNA-transfected 
samples. For the other sub-group, BSA was added into 
conditioned cell culture media from cells transfected 
with control siRNA or MALAT1 siRNAs for comparison. 
The conditioned cell culture media were then added to 
HUVEC cells (Figures 5A, 5B). Vasculature formation 
assays showed that knocking-down MALAT1 expression 
in neuroblastoma cells reduced vasculature formation of 
HUVEC cells, and that addition of FGF2 protein in the 
conditioned cell culture media largely blocked the effect 
of MALAT1 siRNAs on vasculature formation.
We finally transfected BE(2)-C and Kelly cells with 
control siRNA, FGF2 siRNA-1 or FGF2 siRNA-2 under 
hypoxic conditions for 72 hours. Conditioned cell culture 
media were collected and added into HUVEC cells. 
Vasculature formation assays showed that knocking-down 
FGF2 gene expression in neuroblastoma cells reduced 
HUVEC cell vasculature formation (Figures 6A, 6B). In 
addition, knocking-down FGF2 expression in HUVEC 
cells also reduced vasculature formation (Figure 6C).
Taken together, the data suggest that MALAT1-
mediated FGF2 protein secretion from neuroblastoma 
cells induces vasculature formation.
DISCUSSION
During tumor progression, hypoxia develops due 
to rapid tumor growth and consequent oxygen deficiency. 
The profound ability of tumors to activate an angiogenic 
switch under hypoxic conditions and to thereafter trigger 
angiogenesis is considered a hallmark of malignancies [3]. 
While neuroblastoma is well known to be characterized by 
extensive angiogenesis [2], it is not clear which factors are 
important for neuroblastoma-driven angiogenesis.
The long noncoding RNA MALAT1 is highly 
expressed in tumor cells of various organ origins, and is 
expressed at higher levels in metastatic, compared with 
primary, tumor tissues [11, 12, 17]. We have previously 
shown that MALAT1 gene expression is up-regulated 
by the histone demethylase JMJD1A, which is over-
expressed in neuroblastoma cells due to N-Myc oncogene 
amplification, and that MALAT1 induces neuroblastoma 
cell migration and invasion [16]. In this study, we have 
found that MALAT1 expression is significantly up-
regulated in neuroblastoma cells under hypoxic conditions, 
compared with normoxic conditions. As HIF1α is well-
known to be the master factor in hypoxia-driven gene 
transcription, it is likely that up-regulation of MALAT1 
under hypoxic conditions is due to HIF1α. While 
knocking-down MALAT1 does not have an effect on 
neuroblastoma cell proliferation, conditioned media from 
neuroblastoma cells transfected with MALAT1 siRNAs, 
compared with conditioned media from control siRNA-
transfected neuroblastoma cells, induces less endothelial 
cell migration, invasion and vasculature formation under 
hypoxic conditions. The data suggest that up-regulation of 
MALAT1 by hypoxia contributes to neuroblastoma-driven 
angiogenesis.
Genetic ablation of MALAT1 in endothelial cells has 
been reported to reduce neonatal retina vascularization [20]. 
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Table 1: The top genes considerably down- or up-regulated by MALAT1 siRNAs in neuroblastoma cells under 
hypoxic conditions 









































BE(2)-C cells were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 for 30 hours under hypoxic 
conditions. RNA was extracted from the cells, and subjected to differential gene expression study with Affymetrix 
microarray.
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Figure 4: MALAT1 up-regulates FGF2 gene expression in neuroblastoma cells and FGF2 protein secretion under 
hypoxia conditions. A. BE(2)-C and Kelly cells were cultured under normoxic or hypoxic conditions for 48 hours. FGF2 gene 
expression was examined by real-time RT-PCR. B & C. BE(2)-C and Kelly cells were transfected with control siRNA, MALAT1 siRNA-1 
or MALAT1 siRNA-2 under hypoxic conditions for 48 hours, followed by RT-PCR (B) and immunoblot (C) analyses of FGF2 mRNA and 
protein expression respectively. FGF2 protein expression in the immunoblot data was semi-quantified. D. BE(2)-C and Kelly cells were 
transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 under hypoxic conditions for 72 hours. Cell culture media were 
collected, and subjected to ELISA analysis of FGF2 protein expression. Error bars represented standard error. *, ** and *** indicated 
p < 0.05, 0.01 and 0.001 respectively.
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In the current study, our data show that knocking down 
MALAT1 gene expression in endothelial cells considerably 
reduces vasculature formation under both hypoxic and 
normoxic conditions. However, knocking-down MALAT1 
gene expression in endothelial cells has no effect on 
endothelial cell proliferation. Our findings therefore suggest 
that MALAT1 expression plays a dual role in tumor-driven 
angiogenesis, indirectly through MALAT1-mediated 
crosstalk between tumor cells and endothelial cells and 
directly through endothelial cells, and that targeting 
this long noncoding RNA may be an effective strategy 
for blocking both tumor metastasis and angiogenesis 
in neuroblastoma. While no small molecule inhibitors 
specifically targeting MALAT1 are currently available, 
resveratrol has been shown to down-regulate MALAT1, 
resulting in decreased Wnt/beta-catenin signalling, 
reduced cancer cell invasion and metastasis [21]. Whether 
resveratrol can be used to block MALAT1 expression, 
tumor metastasis and angiogenesis in vivo needs further 
investigation.
Figure 5: MALAT1-mediated FGF2 protein secretion from neuroblastoma cells induces vasculature formation. A & B. 
BE(2)-C (A) and Kelly (B) neuroblastoma cells were transfected with control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 for 72 hours 
under hypoxic condition. Cell culture media were collected and divided into two groups. BSA or recombinant FGF2 protein was added 
into the conditioned cell culture media, according to the ELISA data (Figure 4D), so that the levels of FGF2 protein in MALAT1 siRNA-
transfected samples were the same as in control siRNA-transfected samples. The conditioned cell culture media with BSA or recombinant 
FGF2 protein were then added to HUVEC cells in 24-well plates coated with matrigel for 8 hours at 37°C. Photographs of vascular structures 
were taken using a 5 × objective. Vasculature formation was evaluated by measuring the total surface area of capillary tubes formed in at 
least 10 randomly selected fields per well. Scale bars represented 100 μm. Error bars represented standard error. *** indicated p < 0.001.
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lncRNAs are well known to exert biological effects 
by regulating chromatin status to alter gene transcription 
[6, 7] and by acting as a competing endogenous RNA 
to increase target mRNA stability [22]. In this study, 
our microarray differential gene expression study has 
identified several genes, including FGF2, significantly 
regulated by MALAT1 in neuroblastoma cells under 
hypoxic conditions. While none of the other MALAT1 
target genes identified by the microarray data is known 
to regulate endothelial cell function, FGF2 has been well-
documented to regulate endothelial cell migration and 
vasculature formation via activation of Fibroblast Growth 
Factor Receptor, and is one of the most important pro-
angiogenic factors [23]. FGFR2 signaling also induces 
chemoresistance in neuroblastoma cells through protein 
kinase C-δ-dependent induction of BCL2 expression 
[24]. Consistently, treatment with FGF2 vaccine results in 
abrogation of angiogenesis and tumor development [25].
In this study, RT-PCR and immunoblot analyses 
confirm that MALAT1 siRNAs reduce FGF2 mRNA 
and protein expression, and ELISA assays confirm that 
knocking-down MALAT1 expression in neuroblastoma 
cells reduces FGF2 protein secretion into extracellular 
fluid. Chromatin immunoprecipitation assays show that 
knocking-down MALAT1 does not have an effect on the 
presence of tri-methylated histone H3 lysine 4 (data not 
shown), a marker for active gene transcription, suggesting 
that MALAT1 up-regulates FGF2 mRNA through a post-
transcriptional mechanism, possibly through acting as a 
competing endogenous RNA and increasing FGF2 mRNA 
stability. Importantly, we have further demonstrated that 
addition of recombinant FGF2 protein into conditioned 
cell culture media from neuroblastoma cells transfected 
with MALAT1 siRNAs largely blocks MALAT1 siRNA-
mediated reduction in vasculature formation of endothelial 
cells. In addition, knocking-down FGF2 expression in 
Figure 6: Knocking-down FGF2 expression in neuroblastoma or endothelial cells reduces vasculature formation. 
A & B. BE(2)-C (A) and Kelly (B) neuroblastoma cells were transfected with control siRNA, FGF2 siRNA-1 or FGF2 siRNA-2 for 
72 hours under hypoxic conditions. Cell culture media were collected and added to HUVEC cells in 24-well plates coated with matrigel for 
8 hours at 37°C. C. HUVEC cells were transfected with control siRNA, FGF2 siRNA-1 or FGF2 siRNA-2 for 72 hours. Equal numbers 
of transfected HUVEC cells were then plated into matrigel coated 24-well plates for 8 hours at 37°C. Photographs of vascular structures 
were taken using a 5 × objective. Vasculature formation was evaluated by measuring the total surface area of capillary tubes formed in at 
least 10 randomly selected fields per well. Scale bars represented 100 μm. Error bars represented standard error. *** indicated p < 0.001.
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neuroblastoma cells or endothelial cells both reduces 
vasculature formation. Taken together, our data suggest 
that MALAT1 gene expression in human neuroblastoma 
cells induces vasculature formation of endothelial cells 
mainly through up-regulating FGF2 gene expression.
In summary, MALAT1 gene expression is up-
regulated in neuroblastoma cells following hypoxia. 
While up-regulation of MALAT1 does not promote 
neuroblastoma cell proliferation, it up-regulates FGF2 
mRNA and protein expression in neuroblastoma cells 
and increases FGF2 protein secretion into extracellular 
fluid, leading to endothelial cell migration, invasion and 
vasculature formation. MALAT1 gene up-regulation under 
hypoxic condition, therefore, plays an important role in 
tumor-driven angiogenesis and represents a potentially 
valuable therapeutic target for the treatment of this disease.
MATERIALS AND METHODS
Cancer cell line culture
Human BE(2)-C and Kelly neuroblastoma cells 
were cultured in Dulbecco’s modified Eagle’s and RPMI 
1640 media, respectively, supplemented with 10% fetal 
calf serum. BE(2)-C cells were obtained from American 
Type Culture Collection, and Kelly cells from European 
Collection of Cell Cultures. The identity of the cell lines 
was verified by small tandem repeat profiling conducted 
at Garvan Institute and Cellbank Australia (Sydney, 
New South Wales, Australia). Cells were cultured under 
normoxic (with gas mixture containing 21% O2, 5% 
CO2 and 74% nitrogen) or hypoxic (with gas mixture 
containing 1% O2, 5% CO2 and 94% nitrogen) condition.
Endothelial cell culture
HUVEC cells were purchased from American 
Type Culture Collection, and maintained in Medium 
199 supplemented with 20% fetal bovine serum, 5% 
human serum (Sigma, St Louis, MO), 10 U/ml heparin 
(Pharmacia & Upjohn, Peapack, NJ), 5 ng/ml FGF2 
(Sigma) and 20 μg/mL Endothelial Cell Growth Factor 
(Roche, Mannheim, Germany). Only passage five HUVEC 
cells were used in the experiments.
siRNA and plasmid transfection
Cells were transfected with siRNAs from Qiagen 
(Qiagen, Hamburg, Germany) or Ambion (Ambion, 
Austin, TX, USA) using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA) reagent as previously described [8, 26]. The 
target sequences for MALAT1 siRNA-1 and MALAT1 
siRNA-2 were CACAGGGAAAGCGAGUGGUUGGU 
and GACAGGUAUCUCUUCGUUA, and 
those for FGF2 siRNA-1 and FGF2 siRNA-2 
TAGCACTAGTCTTAAATTGTA and AACAATATTA 
GTCGTATCCAA.
RT-PCR and immunoblot analyses
Gene expression in tumor and HUVEC cells 
was examined by quantitative real-time RT-PCR as 
described previously [8, 26]. Sequences of specific 




and 5’-ACTGCCCAGTTCGTTTCAGT-3’ for 
FGF2; and 5’-AGGCCAACCGCGAGAAG-3’ and 
5’-ACAGCCTGGATAGCAACGTACA-3’ for β-actin. 
For the analysis of protein expression by immunoblot, 
cells were lysed, protein extracted and separated by gel 
electrophoresis. After western transfer, membranes were 
probed with rabbit anti-FGF2 antibody (1:250) (Santa 
Cruz Biotech, Santa Cruz, CA), followed by horseradish 
peroxidase-conjugated anti-rabbit (1:10,000) antiserum 
(Santa Cruz Biotech, Santa Cruz, CA). Protein bands were 
visualized with SuperSignal (Pierce, Rockford, IL). The 
membranes were lastly re-probed with a mouse anti-actin 
antibody (Sigma) as loading controls.
FGF2 protein ELISA
BE(2)-C and Kelly cells were transfected with 
control siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2 
under hypoxic condition for 72 hours. Cell culture media 
was collected and subjected to measurement of FGF2 
protein with the sandwich ELISA kit (R&D Systems, 
Minneapolis, MN), as described by the manufacturer. 
Plates were read with a microplate reader at 450 nm with 
background correction at 570 nm.
Affymetrix gene array study
BE(2)-C neuroblastoma cells were transfected 
with scrambled control siRNA, MALAT1 siRNA-1 or 
MALAT1 siRNA-2. Thirty hours after transfection, 
RNA was extracted from the cells with RNeasy mini kit 
(Qiagen). Differential gene expression was examined with 
Affymetrix HuGene-1_0-st-v1 Arrays (Affymetrix, Santa 
Clara, CA), according to the manufacturer’s instructions. 
The LimmaGP module (Gene Pattern, Broad Institute, 
Cambridge, MA) was used to identify genes differentially 
expressed between samples.
Cell proliferation assays
Cell proliferation was examined with Alamar blue 
assays [27]. Briefly, cells were plated into 96 well plates, 
transfected with various siRNAs and grown under hypoxic 
conditions. Seventy-two hours later, cells were incubated 
with Alamar blue (Invitrogen) for 6 hours, and plates 
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were then read on a micro-plate reader at 570/595 nm. 
Results were calculated according to the optical density 
absorbance units and expressed as percentage changes in 
cell numbers.
Transwell HUVEC cell migration assays
Transwell chemotaxis cell migration assays were 
performed as previously described [28]. Briefly, the 
underside of 8 μm transparent polyethylene terephthalate 
membrane inserts (BD Biosciences, San Jose, CA) 
was pre-coated with 0.1% gelatin for 1 hour. The cells 
were pre-labeled in situ with 10 μM Cell Tracker 
Green CMFDA (Invitrogen) in serum-free medium for 
30 minutes and 100,000 cells were then seeded onto the 
insert in serum-free assay medium containing 0.5% BSA. 
Assay medium supplemented with 5% fetal calf serum 
was then added to the bottom of the insert and used as 
chemoattractant. A negative control was included in each 
experiment by adding serum-free medium to the bottom 
of the insert. The plates were incubated for 6 hours at 
37°C and 5% CO2. Excess cells on the upper side of the 
insert were then gently swabbed off with a cotton tip and 
migrated cells at the underside of the insert were measured 
with a Victor 3 plate reader (Perkin-Elmer, Glen Waverley, 
Australia) at 492/517 (Absorbance/Emission). All readings 
were normalized to the negative control (serum-free 
medium).
HUVEC cell invasion assays
HUVEC cell invasion assays were carried out using 
BD BioCoat Growth Factor Reduced Matrigel Invasion 
Chambers according to the manufacturer’s guidelines 
(BD Biosciences) and as we described previously [29]. 
Neuroblastoma cells were transfected with control 
siRNA, MALAT1 siRNA-1 or MALAT1 siRNA-2, 
followed by serum starvation for 72 hours and collection 
of conditioned cell culture media. The neuroblastoma 
cell conditioned media were added into the lower part of 
cell invasion chambers. HUVEC cells were plated into 
the upper part of the invasion chambers and allowed to 
invade through membranes coated with matrigel towards 
the conditioned cell culture media overnight for 18 hours 
at 37°C. Cells invaded through the membrane were fixed 
with 100% methanol, stained with May-Grunwald and 
Giemsa (Sigma-Aldrich), visualized using the Olympus 
BH-2 microscope and quantified.
HUVEC cell vasculature formation assays
Matrigel (BD Biosciences) was diluted 1:1 in M199 
medium supplemented with 0.1% fetal calf serum, 10U/
ml heparin, 5 ng/ml FGF2, 20 μg/ ml Endothelial Cell 
Growth Factor and 29.2 mg/ml glutamine. The Matrigel 
solution was dispensed into 24-well plates and incubated 
for 1 hour at 37°C. HUVEC cells were overlaid onto the 
Matrigel at 7.5 × 104 cells per well and incubated at 37°C 
for 8 hours. Vascular structures (enclosed polygons) were 
photographed using the 5 × objective of an Axiovert 200M 
fluorescent microscope coupled to an AxioCamMR3 
camera (Carl Zeiss, Munich, Germany). Ten fields of 
views were photographed for each condition and the 
numbers of vascularature-like structures were quantified 
using the Zeiss AxioVision 4.7 Image Analysis software.
Statistical analysis
All experiments were repeated for at least 3 times 
for statistical analysis. All data for statistical analysis were 
calculated as mean ± standard error. Differences were 
analyzed for significance using ANOVA among groups or 
unpaired t-test for two groups. A probability value of 0.05 
or less was considered significant.
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